Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate how effective and cost saving 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) is as opposed to the transfusion of blood products in preventing bleeding after teeth extraction in persons with severe liver disease being evaluated for liver transplant.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Icahn School of Medicine at Mount Sinai
• Treatments: Deamino Arginine Vasopressin

Criteria

Inclusion Criteria:

• adult patients with biopsy-proven liver cirrhosis or clinical/radiological evidence of cirrhosis, requiring dental extraction

• platelet count of 30,000-50,000/microL and/or INR 2.0-3.0

Exclusion Criteria:

• the presence of other bleeding disorders besides cirrhosis such as renal dysfunction (creatinine > 2.0) or HIV

• receipt of blood transfusion within 2 weeks prior to study

• recent acute decompensation of liver cirrhosis

• malignancy excluding hepatocellular carcinoma in the absence of portal vein thrombosis

• treatment with anti-platelet medications (aspirin, non-steroidal anti-inflammatory drugs or clopidogrel) within ten days prior to the extraction

• documented allergy to DDAVP.